



2020

Step Therapy Requirements

Effective: 04/01/2020
Last updated 03/24/2020



AMANTADINE ER

Products Affected

Step 2:

- OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE
- OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
-----------------	----------------------------------------------------------------------------

AMLODIPINE ORAL SUSPENSION

Products Affected

Step 2:

- KATERZIA 1 MG/ML ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC AMLODIPINE TABLETS WITHIN THE PAST 120 DAYS.
-----------------	----------------------------------------------------------------------

ANTIDEPRESSANTS

Products Affected

Step 2:

- FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK
- FETZIMA 20 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 40 MG
CAPSULE,EXTENDED RELEASE
- FETZIMA 80 MG
CAPSULE,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR TRINTELLIX AND VIIBRYD WITHIN THE PAST 365 DAYS.
-----------------	------------------------------------------------------------------

ANTIDIABETIC AGENTS - MISCELLANEOUS

Products Affected

Step 2:

- GLYXAMBI 10 MG-5 MG TABLET
- GLYXAMBI 25 MG-5 MG TABLET
- INVOKAMET 150 MG-1,000 MG TABLET
- INVOKAMET 150 MG-500 MG TABLET
- INVOKAMET 50 MG-1,000 MG TABLET
- INVOKAMET 50 MG-500 MG TABLET
- INVOKAMET XR 150 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE
- INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE
- INVOKANA 100 MG TABLET
- INVOKANA 300 MG TABLET
- JARDIANCE 10 MG TABLET
- JARDIANCE 25 MG TABLET
- SYNJARDY 12.5 MG-1,000 MG TABLET
- SYNJARDY 12.5 MG-500 MG TABLET
- SYNJARDY 5 MG-1,000 MG TABLET
- SYNJARDY 5 MG-500 MG TABLET
- SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE
- SYNJARDY XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR METFORMIN, METFORMIN ER, A SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE), PIOGLITAZONE, OR COMBINATION OF A SULFONYLUREA-METFORMIN WITHIN THE PAST 120 DAYS.
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANTI-INFLAMMATORY AGENTS - GI

Products Affected

Step 2:

- DIPENTUM 250 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR 1 OF THE FOLLOWING: BALSALAZIDE, FORMULARY VERSION OF MESALAMINE 0.375G, MESALAMINE 400 MG CAP(DRTAB), MESALAMINE DR 800 MG TAB, OR FORMULARY VERSION OF MESALAMINE 1.2 G DR TAB WITHIN THE PAST 120 DAYS.
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANTIPSYCHOTIC AGENTS

Products Affected

Step 2:

- *aripiprazole 10 mg disintegrating tablet*
- *aripiprazole 15 mg disintegrating tablet*
- CAPLYTA 42 MG CAPSULE
- *clozapine 100 mg disintegrating tablet*
- *clozapine 12.5 mg disintegrating tablet*
- *clozapine 150 mg disintegrating tablet*
- *clozapine 200 mg disintegrating tablet*
- *clozapine 25 mg disintegrating tablet*
- FANAPT 1 MG TABLET
- FANAPT 10 MG TABLET
- FANAPT 12 MG TABLET
- FANAPT 1MG(2)-2 MG(2)-4MG(2)-6 MG(2) TABLETS IN A DOSE PACK
- FANAPT 2 MG TABLET
- FANAPT 4 MG TABLET
- FANAPT 6 MG TABLET
- FANAPT 8 MG TABLET
- SAPHRIS 10 MG SUBLINGUAL TABLET
- SAPHRIS 2.5 MG SUBLINGUAL TABLET
- SAPHRIS 5 MG SUBLINGUAL TABLET
- SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH
- VERSACLOZ 50 MG/ML ORAL SUSPENSION
- VRAYLAR 1.5 MG (1)-3 MG (6) CAPSULES IN A DOSE PACK
- VRAYLAR 1.5 MG CAPSULE
- VRAYLAR 3 MG CAPSULE
- VRAYLAR 4.5 MG CAPSULE
- VRAYLAR 6 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSIONS OF ANY TWO ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE WITHIN THE PAST 365 DAYS.
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANTIPSYCHOTIC AGENTS II

Products Affected

Step 2:

- REXULTI 0.25 MG TABLET
- REXULTI 0.5 MG TABLET
- REXULTI 1 MG TABLET
- REXULTI 2 MG TABLET
- REXULTI 3 MG TABLET
- REXULTI 4 MG TABLET

Details

Criteria	PRIOR CLAIM FOR TWO (2) OF THE FOLLOWING FORMULARY ORAL VERSIONS OF ATYPICAL ANTIPSYCHOTICS (RISPERIDONE, CLOZAPINE, OLANZAPINE, QUETIAPINE, ARIPIPRAZOLE OR ZIPRASIDONE) OR SSRI (CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE OR SERTRALINE) OR SNRI (DESVENLAFAXINE, DULOXETINE OR VENLAFAXINE) WITHIN THE PAST 365 DAYS
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANTIULCER AGENTS

Products Affected

Step 2:

- DEXILANT 30 MG CAPSULE, DELAYED RELEASE
- DEXILANT 60 MG CAPSULE, DELAYED RELEASE
- *omeprazole 20 mg-sodium bicarbonate 1.1 gram capsule*
- *omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule*
- *rabeprazole 20 mg tablet, delayed release*

Details

Criteria	PRIOR CLAIM FOR GENERIC FEDERAL LEGEND FORMULARY VERSION OF ORAL LANSOPRAZOLE CAPSULES, OMEPRAZOLE, OR PANTOPRAZOLE WITHIN THE PAST 120 DAYS.
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------

B VERSUS D ADMINISTRATIVE STEP

Products Affected

Step 2:

- CYCLOPHOSPHAMIDE 25 MG CAPSULE
- CYCLOPHOSPHAMIDE 50 MG CAPSULE
- *methotrexate sodium 2.5 mg tablet*
- XATMEP 2.5 MG/ML ORAL SOLUTION

Details

Criteria	IN ORDER TO ASSIST IN A PART B VS. D PAYMENT DETERMINATION, A PRIOR CLAIM SEEN FOR A RHEUMATOID ARTHRITIS, PSORIASIS OR ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG WITHIN THE PAST 120 DAYS WILL QUALIFY FOR PART D PAYMENT. ALL OTHER INDICATIONS WILL HAVE A PART B VS. D PAYMENT DETERMINATION MADE THROUGH THE FORMULARY EXCEPTION PROCESS PRIOR TO THE APPROVAL OF THE DRUG.
-----------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DPP-4 INHIBITORS

Products Affected

Step 2:

- JENTADUETO 2.5 MG-1,000 MG TABLET
- JENTADUETO 2.5 MG-500 MG TABLET
- JENTADUETO 2.5 MG-850 MG TABLET
- JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE
- JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE
- TRADJENTA 5 MG TABLET

Details

Criteria	PRIOR CLAIM FOR JANUMET, JANUMET XR OR JANUVIA WITHIN THE PAST 120 DAYS
-----------------	-------------------------------------------------------------------------

DULOXETINE SPRINKLE

Products Affected

Step 2:

- DRIZALMA SPRINKLE 20 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 30 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 40 MG CAPSULE,DELAYED RELEASE
- DRIZALMA SPRINKLE 60 MG CAPSULE,DELAYED RELEASE

Details

Criteria	PRIOR CLAIM FOR FORMULARY GENERIC DULOXETINE CAPSULE WITHIN THE PAST 120 DAYS.
-----------------	--------------------------------------------------------------------------------

ELUXADOLINE

Products Affected

Step 2:

- VIBERZI 100 MG TABLET
- VIBERZI 75 MG TABLET

Details

Criteria	PRIOR CLAIM FOR DICYCLOMINE AND XIFAXAN 550MG WITHIN THE PAST 365 DAYS.
-----------------	-------------------------------------------------------------------------

ENALAPRIL ORAL SOLUTION

Products Affected

Step 2:

- EPANED 1 MG/ML ORAL SOLUTION

Details

Criteria	PRIOR CLAIM FOR GENERIC ENALAPRIL ORAL WITHIN THE PAST 120 DAYS.
-----------------	------------------------------------------------------------------

FIDAXOMICIN

Products Affected

Step 2:

- DIFICID 200 MG TABLET

Details

Criteria	PRIOR CLAIM FOR ORAL VANCOMYCIN IN THE PAST 120 DAYS.
-----------------	-------------------------------------------------------

GABAPENTIN SR

Products Affected

Step 2:

- GRALISE 300 MG
TABLET,EXTENDED RELEASE
- GRALISE 30-DAY STARTER PACK
300 MG (9)-600 MG (69) TABLET,EXT.
RELEASE
- GRALISE 600 MG
TABLET,EXTENDED RELEASE

Details

Criteria	PRIOR CLAIM FOR GABAPENTIN IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
-----------------	------------------------------------------------------------------------

INSULIN/GLP-1 ANALOG

Products Affected

Step 2:

- SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN
- XULTOPHY 100/3.6 100 UNIT-3.6 MG/ML (3 ML) SUBCUTANEOUS INSULIN PEN

Details

Criteria	PRIOR CLAIM FOR 2 OF THE FOLLOWING (ONE FROM EACH GROUP): A) LANTUS, LANTUS SOLOSTAR, OZEMPIC, TRESIBA, TRESIBA FLEXTOUCH, TOUJEO MAX SOLOSTAR, TOUJEO SOLOSTAR OR VICTOZA AND B) METFORMIN, METFORMIN ER, SULFONYLUREA AGENT (GLYBURIDE, GLIPIZIDE, GLIMEPIRIDE), COMBO SULFONYLUREA- METFORMIN, OR PIOGLITAZONE IN PAST 365 DAYS.
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LISINOPRIL ORAL SOLUTION

Products Affected

Step 2:

- QBRELIS 1 MG/ML ORAL SOLUTION

Details

Criteria	PRIOR CLAIM FOR GENERIC LISINOPRIL WITHIN THE PAST 120 DAYS.
-----------------	--------------------------------------------------------------

NASAL CORTICOSTEROIDS II

Products Affected

Step 2:

- XHANCE 93 MCG/ACTUATION
BREATH ACTIVATED AEROSOL

Details

Criteria	PRIOR CLAIM FOR A FEDERAL LEGEND FORMULARY VERSION OF MOMETASONE NASAL SPRAY WITHIN THE PAST 120 DAYS
-----------------	-------------------------------------------------------------------------------------------------------

NOVEL ORAL ANTICOAGULANTS

Products Affected

Step 2:

- PRADAXA 110 MG CAPSULE
- PRADAXA 150 MG CAPSULE
- PRADAXA 75 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR ELIQUIS AND XARELTO IN THE PAST 365 DAYS.
-----------------	-----------------------------------------------------------

OPHTHALMIC ALLERGY - NO OTC

Products Affected

Step 2:

- ALREX 0.2 % EYE DROPS,SUSPENSION
- BEPREVE 1.5 % EYE DROPS

Details

Criteria	PRIOR CLAIM FOR FEDERAL LEGEND LEVOCETIRIZINE , CROMOLYN SODIUM, EPINASTINE, OR FORMULARY OLOPATADINE EYE DROPS WITHIN THE PAST 120 DAYS.
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------

OPHTHALMIC PROSTAGLANDINS

Products Affected

Step 2:

- ROCKLATAN 0.02 %-0.005 % EYE DROPS
- XELPROS 0.005 % EYE DROP EMULSION

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF LATANOPROST (GENERIC XALATAN OR XALATAN) AND ONE OF THE FOLLOWING: ALPHAGAN P 0.1%, AZOPT, COMBIGAN, LUMIGAN 0.01%, SIMBRINZA OR FORMULARY VERSION OF TRAVOPROST WITHIN THE PAST 365 DAYS.
-----------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RENIN ANGIOTENSIN SYSTEM INHIBITORS

Products Affected

Step 2:

- TEKTURNA HCT 150 MG-12.5 MG TABLET
- TEKTURNA HCT 150 MG-25 MG TABLET
- TEKTURNA HCT 300 MG-12.5 MG TABLET
- TEKTURNA HCT 300 MG-25 MG TABLET

Details

Criteria	PRIOR CLAIM FOR AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE INHIBITOR), ACE INHIBITOR COMBINATION, GENERIC ANGIOTENSIN RECEPTOR BLOCKER (ARB), GENERIC ARB COMBINATION OR GENERIC DIRECT RENIN INHIBITORS WITHIN THE PAST 120 DAYS.
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ROSUVASTATIN SPRINKLE

Products Affected

Step 2:

- EZALLOR SPRINKLE 10 MG CAPSULE
- EZALLOR SPRINKLE 20 MG CAPSULE
- EZALLOR SPRINKLE 40 MG CAPSULE
- EZALLOR SPRINKLE 5 MG CAPSULE

Details

Criteria	PRIOR CLAIM FOR GENERIC ROSUVASTATIN TABLET IN THE PAST 120 DAYS.
-----------------	-------------------------------------------------------------------

SIMVASTATIN ORAL SUSPENSION

Products Affected

Step 2:

- FLOLIPID 20 MG/5 ML (4 MG/ML)
ORAL SUSPENSION
- FLOLIPID 40 MG/5 ML (8 MG/ML)
ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC SIMVASTATIN ORAL TABLETS WITHIN THE PAST 120 DAYS.
-----------------	-------------------------------------------------------------------------------

SPIRONOLACTONE ORAL SUSPENSION

Products Affected

Step 2:

- CAROSPIR 25 MG/5 ML ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR GENERIC SPIRONOLACTONE WITHIN THE PAST 120 DAYS.
-----------------	------------------------------------------------------------------

SPRITAM

Products Affected

Step 2:

- SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 250 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 500 MG TABLET FOR ORAL SUSPENSION
- SPRITAM 750 MG TABLET FOR ORAL SUSPENSION

Details

Criteria	PRIOR CLAIM FOR LEVETIRACETAM SOLUTION IN THE PAST 120 DAYS
-----------------	-------------------------------------------------------------

TACROLIMUS PACKETS

Products Affected

Step 2:

- PROGRAF 0.2 MG ORAL GRANULES IN PACKET
- PROGRAF 1 MG ORAL GRANULES IN PACKET

Details

Criteria	PRIOR CLAIM FOR FORMULARY VERSION OF TACROLIMUS CAPSULES WITHIN THE PAST 120 DAYS
-----------------	-----------------------------------------------------------------------------------

INDEX

A

ALREX 0.2 % EYE DROPS,SUSPENSION 20
aripiprazole 10 mg disintegrating tablet 6
aripiprazole 15 mg disintegrating tablet 6

B

BEPREVE 1.5 % EYE DROPS 20

C

CAPLYTA 42 MG CAPSULE 6
CAROSPIR 25 MG/5 ML ORAL
SUSPENSION 25
clozapine 100 mg disintegrating tablet 6
clozapine 12.5 mg disintegrating tablet 6
clozapine 150 mg disintegrating tablet 6
clozapine 200 mg disintegrating tablet 6
clozapine 25 mg disintegrating tablet 6
CYCLOPHOSPHAMIDE 25 MG
CAPSULE 9
CYCLOPHOSPHAMIDE 50 MG
CAPSULE 9

D

DEXILANT 30 MG CAPSULE,
DELAYED RELEASE 8
DEXILANT 60 MG CAPSULE,
DELAYED RELEASE 8
DIFICID 200 MG TABLET 14
DIPENTUM 250 MG CAPSULE 5
DRIZALMA SPRINKLE 20 MG
CAPSULE,DELAYED RELEASE 11
DRIZALMA SPRINKLE 30 MG
CAPSULE,DELAYED RELEASE 11
DRIZALMA SPRINKLE 40 MG
CAPSULE,DELAYED RELEASE 11
DRIZALMA SPRINKLE 60 MG
CAPSULE,DELAYED RELEASE 11

E

EPANED 1 MG/ML ORAL SOLUTION 13
EZALLOR SPRINKLE 10 MG CAPSULE
..... 23
EZALLOR SPRINKLE 20 MG CAPSULE
..... 23
EZALLOR SPRINKLE 40 MG CAPSULE
..... 23
EZALLOR SPRINKLE 5 MG CAPSULE 23

F

FANAPT 1 MG TABLET 6
FANAPT 10 MG TABLET 6
FANAPT 12 MG TABLET 6
FANAPT 1MG(2)-2 MG(2)-4MG(2)-6
MG(2) TABLETS IN A DOSE PACK... 6
FANAPT 2 MG TABLET 6
FANAPT 4 MG TABLET 6
FANAPT 6 MG TABLET 6
FANAPT 8 MG TABLET 6
FETZIMA 120 MG
CAPSULE,EXTENDED RELEASE 3
FETZIMA 20 MG (2)-40 MG (26)
CAPSULE,EXTENDED RELEASE,24
HR,DOSE PACK 3
FETZIMA 20 MG CAPSULE,EXTENDED
RELEASE 3
FETZIMA 40 MG CAPSULE,EXTENDED
RELEASE 3
FETZIMA 80 MG CAPSULE,EXTENDED
RELEASE 3
FLOLIPID 20 MG/5 ML (4 MG/ML)
ORAL SUSPENSION 24
FLOLIPID 40 MG/5 ML (8 MG/ML)
ORAL SUSPENSION 24

G

GLYXAMBI 10 MG-5 MG TABLET 4
GLYXAMBI 25 MG-5 MG TABLET 4
GRALISE 300 MG TABLET,EXTENDED
RELEASE 15
GRALISE 30-DAY STARTER PACK 300
MG (9)-600 MG (69) TABLET,EXT.
RELEASE 15
GRALISE 600 MG TABLET,EXTENDED
RELEASE 15

I

INVOKAMET 150 MG-1,000 MG
TABLET 4
INVOKAMET 150 MG-500 MG TABLET 4
INVOKAMET 50 MG-1,000 MG TABLET
..... 4
INVOKAMET 50 MG-500 MG TABLET. 4
INVOKAMET XR 150 MG-1,000 MG
TABLET, EXTENDED RELEASE 4

INVOKAMET XR 150 MG-500 MG TABLET, EXTENDED RELEASE	4
INVOKAMET XR 50 MG-1,000 MG TABLET, EXTENDED RELEASE	4
INVOKAMET XR 50 MG-500 MG TABLET, EXTENDED RELEASE	4
INVOKANA 100 MG TABLET	4
INVOKANA 300 MG TABLET	4
J	
JARDIANCE 10 MG TABLET	4
JARDIANCE 25 MG TABLET	4
JENTADUETO 2.5 MG-1,000 MG TABLET	10
JENTADUETO 2.5 MG-500 MG TABLET	10
JENTADUETO 2.5 MG-850 MG TABLET	10
JENTADUETO XR 2.5 MG-1,000 MG TABLET, EXTENDED RELEASE	10
JENTADUETO XR 5 MG-1,000 MG TABLET, EXTENDED RELEASE	10
K	
KATERZIA 1 MG/ML ORAL SUSPENSION	2
M	
methotrexate sodium 2.5 mg tablet	9
O	
omeprazole 20 mg-sodium bicarbonate 1.1 gram capsule	8
omeprazole 40 mg-sodium bicarbonate 1.1 gram capsule	8
OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE	1
OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE	1
OSMOLEX ER 258 MG TABLET, EXTENDED RELEASE	1
P	
PRADAXA 110 MG CAPSULE	19
PRADAXA 150 MG CAPSULE	19
PRADAXA 75 MG CAPSULE	19
PROGRAF 0.2 MG ORAL GRANULES IN PACKET	27
PROGRAF 1 MG ORAL GRANULES IN PACKET	27

Q	
QBRELIS 1 MG/ML ORAL SOLUTION	17
R	
rabeprazole 20 mg tablet, delayed release ...	8
REXULTI 0.25 MG TABLET	7
REXULTI 0.5 MG TABLET	7
REXULTI 1 MG TABLET	7
REXULTI 2 MG TABLET	7
REXULTI 3 MG TABLET	7
REXULTI 4 MG TABLET	7
ROCKLATAN 0.02 %-0.005 % EYE DROPS	21
S	
SAPHRIS 10 MG SUBLINGUAL TABLET	6
SAPHRIS 2.5 MG SUBLINGUAL TABLET	6
SAPHRIS 5 MG SUBLINGUAL TABLET	6
SECUADO 3.8 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH ...	6
SECUADO 5.7 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH ...	6
SECUADO 7.6 MG/24 HOUR TRANSDERMAL 24 HOUR PATCH ...	6
SOLIQUA 100/33 100 UNIT-33 MCG/ML SUBCUTANEOUS INSULIN PEN	16
SPRITAM 1,000 MG TABLET FOR ORAL SUSPENSION	26
SPRITAM 250 MG TABLET FOR ORAL SUSPENSION	26
SPRITAM 500 MG TABLET FOR ORAL SUSPENSION	26
SPRITAM 750 MG TABLET FOR ORAL SUSPENSION	26
SYNJARDY 12.5 MG-1,000 MG TABLET	4
SYNJARDY 12.5 MG-500 MG TABLET	4
SYNJARDY 5 MG-1,000 MG TABLET ...	4
SYNJARDY 5 MG-500 MG TABLET	4
SYNJARDY XR 10 MG-1,000 MG TABLET, EXTENDED RELEASE	4
SYNJARDY XR 12.5 MG-1,000 MG TABLET, EXTENDED RELEASE	4
SYNJARDY XR 25 MG-1,000 MG TABLET, EXTENDED RELEASE	4

SYNJARDY XR 5 MG-1,000 MG
TABLET, EXTENDED RELEASE 4

T

TEKTURNA HCT 150 MG-12.5 MG
TABLET 22

TEKTURNA HCT 150 MG-25 MG
TABLET 22

TEKTURNA HCT 300 MG-12.5 MG
TABLET 22

TEKTURNA HCT 300 MG-25 MG
TABLET 22

TRADJENTA 5 MG TABLET 10

V

VERSACLOZ 50 MG/ML ORAL
SUSPENSION 6

VIBERZI 100 MG TABLET 12

VIBERZI 75 MG TABLET 12

VRAYLAR 1.5 MG (1)-3 MG (6)
CAPSULES IN A DOSE PACK 6

VRAYLAR 1.5 MG CAPSULE 6

VRAYLAR 3 MG CAPSULE 6

VRAYLAR 4.5 MG CAPSULE 6

VRAYLAR 6 MG CAPSULE 6

X

XATMEP 2.5 MG/ML ORAL SOLUTION 9

XELPROS 0.005 % EYE DROP
EMULSION 21

XHANCE 93 MCG/ACTUATION
BREATH ACTIVATED AEROSOL ... 18

XULTOPHY 100/3.6 100 UNIT-3.6
MG/ML (3 ML) SUBCUTANEOUS

INSULIN PEN 16